Royalty Pharma Announces Expansion of Senior Leadership Team
December 15 2022 - 8:15AM
Royalty Pharma plc (Nasdaq: RPRX) today announced the expansion of
its senior leadership team. This expansion highlights Royalty
Pharma’s success in developing a talented, diverse and experienced
leadership team responsible for formulating and executing on its
mission to accelerate innovation and transform patient lives.
The following promotions are effective January 1, 2023, and each
individual will join the Senior Leadership Committee:
- Sara Klymkowsky
will be promoted to Senior Vice President, Research &
Investments. Sara has been an integral member of the Research &
Investments team since joining Royalty Pharma in 2012. She has
played a key role in executing many of Royalty Pharma’s most
important transactions, including investments in the Vertex cystic
fibrosis franchise, Tysabri and Trelegy.
- Brienne Kugler will
be promoted to Senior Vice President, Research & Investments.
Brienne has been a key member of the Research & Investments
team since joining Royalty Pharma in 2014. She has played a major
role in executing many of Royalty Pharma’s most important
transactions, including multiple Biohaven investments, Tremfya and
Evrysdi.
- Alessandra Sassun
will be promoted to Senior Vice President, Head of Human Capital.
Alessandra joined Royalty Pharma in 2020 and is responsible for
overseeing Royalty Pharma’s human resource planning, professional
development and performance management.
“We are delighted to announce the promotions of Sara, Brienne
and Alessandra as well as their addition to Royalty Pharma’s Senior
Leadership Committee,” said Pablo Legorreta, Royalty Pharma’s
founder and Chief Executive Officer. “Sara and Brienne have been
exceptionally strong contributors to Royalty Pharma’s success, and
have led the sourcing, engagement, diligence, and execution of many
of our most important royalty transactions. Alessandra brings deep
experience and diverse perspectives from her many years overseeing
human capital at leading investment firms. I am confident our
strengthened leadership team is well positioned to execute on our
mission of accelerating innovation in life sciences and
transforming patient lives while delivering value for all of our
stakeholders.”
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of
biopharmaceutical royalties and a leading funder of innovation
across the biopharmaceutical industry, collaborating with
innovators from academic institutions, research hospitals and
non-profits through small and mid-cap biotechnology companies to
leading global pharmaceutical companies. Royalty Pharma has
assembled a portfolio of royalties which entitles it to payments
based directly on the top-line sales of many of the industry’s
leading therapies. Royalty Pharma funds innovation in the
biopharmaceutical industry both directly and indirectly - directly
when it partners with companies to co-fund late-stage clinical
trials and new product launches in exchange for future royalties,
and indirectly when it acquires existing royalties from the
original innovators. Royalty Pharma’s current portfolio includes
royalties on more than 35 commercial products, including Vertex’s
Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri, AbbVie
and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s
Xtandi, GSK’s Trelegy, Novartis’ Promacta, Pfizer’s Nurtec ODT,
Johnson & Johnson’s Tremfya, Roche’s Evrysdi, Gilead’s
Trodelvy, and 12 development-stage product candidates.
Forward-Looking Statements
The information set forth herein does not purport to be complete
or to contain all of the information you may desire. Statements
contained herein are made as of the date of this document unless
stated otherwise, and neither the delivery of this document at any
time, nor any sale of securities, shall under any circumstances
create an implication that the information contained herein is
correct as of any time after such date or that information will be
updated or revised to reflect information that subsequently becomes
available or changes occurring after the date hereof. This document
contains statements that constitute “forward-looking statements” as
that term is defined in the United States Private Securities
Litigation Reform Act of 1995, including statements that express
the company’s opinions, expectations, beliefs, plans, objectives,
assumptions or projections regarding future events or future
results, in contrast with statements that reflect historical facts.
Examples include discussion of Royalty Pharma’s strategies,
financing plans, growth opportunities and market growth. In some
cases, you can identify such forward-looking statements by
terminology such as “anticipate,” “intend,” “believe,” “estimate,”
“plan,” “seek,” “project,” “expect,” “may,” “will,” “would,”
“could” or “should,” the negative of these terms or similar
expressions. Forward-looking statements are based on management’s
current beliefs and assumptions and on information currently
available to the company. However, these forward-looking statements
are not a guarantee of Royalty Pharma’s performance, and you should
not place undue reliance on such statements. Forward-looking
statements are subject to many risks, uncertainties and other
variable circumstances, and other factors. Such risks and
uncertainties may cause the statements to be inaccurate and readers
are cautioned not to place undue reliance on such statements. Many
of these risks are outside of Royalty Pharma’s control and could
cause its actual results to differ materially from those it thought
would occur. The forward-looking statements included in this
document are made only as of the date hereof. Royalty Pharma does
not undertake, and specifically declines, any obligation to update
any such statements or to publicly announce the results of any
revisions to any such statements to reflect future events or
developments, except as required by law. Certain information
contained in this document relates to or is based on studies,
publications, surveys and other data obtained from third-party
sources and Royalty Pharma’s own internal estimates and research.
While Royalty Pharma believes these third-party sources to be
reliable as of the date of this document, it has not independently
verified, and makes no representation as to the adequacy, fairness,
accuracy or completeness of, any information obtained from
third-party sources. In addition, all of the market data included
in this document involves a number of assumptions and limitations,
and there can be no guarantee as to the accuracy or reliability of
such assumptions. Finally, while the company believes its own
internal research is reliable, such research has not been verified
by any independent source. For further information, please
reference Royalty Pharma’s reports and documents filed with the
U.S. Securities and Exchange Commission (“SEC”) by visiting EDGAR
on the SEC’s website at www.sec.gov.
Royalty Pharma Investor Relations and
Communications
+1 (212) 883-6772ir@royaltypharma.com
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Jul 2023 to Jul 2024